Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: A Fresh Wave Of Approvals

Apr 22 2018

• By Michael Cipriano and Bridget Silverman

Keeping Track Feature image

Related Content

Hemophilia Patients Call For US FDA Hearing To Assure Access To Hemlibra

Apr 11 2018

Five Hemlibra Deaths But Not Caused By Hemophilia Drug – Roche

Mar 28 2018

Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations

Oct 15 2017

A Biomarker For Bristol: Mutation Burden Shows Promise In Small Cell Lung Cancer

Oct 17 2017

Keeping Track: Breakthrough Therapies Becoming Breakthrough Applications For Tezacaftor, Burosumab, Emicizumab

Aug 28 2017

Genentech's Hemlibra: Clinical Outcome Assessment Data Only Partially Swayed US FDA

Jan 27 2018

Rigel Optimistic On Fostamatinib Despite Narrow Phase III Benefit

Aug 30 2016

Keeping Track: US FDA Approvals Binge Continues With Dupixent, Ocrevus And Zejula; Two CAR-T Are Under Review

Apr 01 2017

Will Ultragenyx/Kyowa Hypophosphatemia Data Support Uptake?

Apr 20 2017

Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

Nov 14 2017

Non-Inhibitor Data Secure Roche's Competitive Position In Hemophilia A

Nov 20 2017

Rigel Readies Tavalisse For Late-May Launch After FDA Approval

Apr 18 2018

Rigel Mulls Next Steps After Fostamatinib Fails In Kidney Disease

Apr 04 2018

Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Apr 17 2018

Ultragenyx Gets Second Drug Approval; Crysvita With Kyowa Hakko Kirin

Apr 18 2018

Related Companies

Ultragenyx Pharmaceutical Inc.

Rigel Pharmaceuticals, Inc.

AstraZeneca PLC

Bristol Myers Squibb Company

Genentech, Inc.

Alkermes plc

Novartis AG

Merck & Co., Inc.

Roche Holding AG

Additional Topics

United States Drug Review Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window